Table 2.
Correlation of ANXA10 mRNA Expression with Clinicopathological Features in 182 Patients with Unifocal Primary Hepatocellular Carcinoma
| ANXA10 mRNA expression | |||
|---|---|---|---|
| Normal expression (n = 61) | Down-regulation (n = 121) | P value | |
| AFP | |||
| <320 ng/ml (n = 97) | 51 | 46 (47%) | <0.00001 |
| ≥320 ng/ml (n = 85) | 10 | 75 (88%) | |
| p53 mutation | |||
| Yes (n = 77) | 19 | 58 (75%) | 0.024 |
| No (n = 79) | 33 | 46 (58%) | |
| Tumor size | |||
| ≤3 cm (n = 45) | 24 | 21 (47%) | 0.0012 |
| >3 cm (n = 137) | 37 | 100 (73%) | |
| Tumor grade | |||
| I (n = 39) | 25 | 14 (36%) | <0.00001 |
| II–III (n = 142) | 36 | 106 (75%) | |
| Tumor stage | |||
| I–II (n = 83) | 42 | 41 (49%) | <0.00001 |
| IIIA–IV (n = 99) | 19 | 80 (81%) | |
| Early recurrence (≤1-yr)* | 14/52 (27%) | 58/104 (56%) | 0.0007 |
*Tumor recurrence in the liver was detected ≤12 months after resection of the primary HCC.